Evercore HC Menlo vs Lazard HC SF
Curious on how these two groups stack up against one another in terms of deal flow, culture, pay, and overall the better place to work (objectively).
Curious on how these two groups stack up against one another in terms of deal flow, culture, pay, and overall the better place to work (objectively).
| +197 | Americas M&A League Table Q2 Updated | 79 | 19m |
| +142 | New Article: Dramatic Slide as UBS #22 (US) & New Leadership Desperately Needed | 38 | 20h |
| +131 | Restructuring: Anti-climactic Experience | 34 | 1d |
| +101 | IB Net Worth / Savings Check | 47 | 8h |
| +90 | Woman who emptied Knicks trashcan on street then stole it was DEI exec, worked at JPMorgan Chase | 24 | 10h |
| +75 | Stop sleeping on UBS - it’s pretty good | 24 | 14h |
| +51 | 2026 VAULT PRESTIGE RANKINGS | 29 | 1d |
| +39 | AI + Financial Modelling | 12 | 21h |
| +28 | Summer before college | 17 | 10h |
| +27 | Hardest interview experiences? | 16 | 19h |
Career Resources
evercore pays more, is much better in terms of dealflow (lowk evercore is top 2 after poaching ben carpenter from JPM) and Laz only had 1 M&A pharma deal in 2025 (and the MD who brought that deal in j left for Leerink M&A), Laz probs has better culture (WFH monday and friday, people are all great). If you are optimizing for a great time pick Laz, if you are optimizing for deal flow, comp, and exits, def go evercore (only better shop is CVP and maybe GS).
Fuck California come to NYC like a real man
If I were in your shoes and had offers from both, I’d take Evercore Menlo over Lazard SF. Not just for the stronger M&A deal flow, but because the Evercore platform in biopharma feels like it has more momentum right now given the mandates they’ve been landing and the overall trajectory of the group with some of the recent hires they've made. You also get the added bonus of getting some capital markets exposure since Evercore’s team is occasionally involved on some impactful IPOs and follow-ons/PIPEs, which I'd argue is important if you possibly want to go down the VC route.
I go more into detail here in case you're interested: [Early 2026] The Definitive and Data-Driven Healthcare IB Group Rankings (Biopharma + Broader HC) | Wall Street Oasis
EVR Menlo HC imo, better platform and trajectory (+ comp too). LAZ HC is not the same as it was
bump
Beatae odio soluta rem at minima. Dolores repudiandae magnam deserunt nihil. Dolor necessitatibus et amet mollitia voluptatem qui in. Et repellendus culpa ea cumque.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...